EndoChoice announces acquisition of Pathworks Anatomic Pathology Laboratory

EndoChoice, Inc. announced today that it has acquired Pathworks Anatomic Pathology Laboratory. Founded in 1989, Pathworks is a College of American Pathologists (CAP) accredited national reference laboratory located in Atlanta, GA. Robert Smith, MD, founder of the laboratory, will assume the Medical Director position of EndoChoice Pathology, a wholly-owned subsidiary of EndoChoice, Inc.  

"We are excited to leverage our GI expertise and join the EndoChoice team. For pathology services, our subspecialty focus ensures quality results. With its complete focus on the GI community, EndoChoice is a natural fit for our organization," said Dr. Smith.  

The EndoChoice GI Diagnostics Division offers the broadest range of diagnostic products and services in the industry, including anatomic pathology services, immunochemical fecal occult blood tests (FIT), H. pylori tests, and the first gene expression tests for inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). EndoChoice Pathology provides high-quality lab services through its gastrointestinal specific and subspecialty- trained pathologists.  

"Our unique ability to provide a comprehensive suite of diagnostic products and services is important to our customers and their patients. This successful acquisition further expands our ability to deliver outstanding clinical services to our physician clients across the nation," said Mark Gilreath, CEO of EndoChoice.

Source:

EndoChoice, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Semaglutide enhances cognitive abilities and reduces Alzheimer’s pathology in mice and human brain models